Daxor Corporation is a diversified, closed-end management investment company. Its focus and operations are as a medical device manufacturing, company. It specializes in blood volume measurement technology focused on blood volume testing innovation. It markets the Blood Volume Analyzer (BVA)-100, the diagnostic blood test cleared by the FDA to provide objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000 tests have been performed at hospital centers across the United States, enhancing hospital performance metrics in a range of surgical and medical conditions, including reducing mortality and readmissions in heart failure and critical care. Its facility provides on-demand, next day blood volume analysis results. It has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the United States Department of Defense.
Ticker SymbolDXR
Company nameDaxor Corp
IPO dateJul 25, 1983
CEOMr. Michael Richard Feldschuh
Number of employees- -
Security typeOrdinary Share
Fiscal year-endJul 25
AddressSuite 7120
CityNEW YORK
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code10118
Phone12122440555
Websitehttps://www.daxor.com/
Ticker SymbolDXR
IPO dateJul 25, 1983
CEOMr. Michael Richard Feldschuh
A total of
0.00
USD has been distributed in dividends over the past 5 years.

No Data